Chordate Medical Holding AB is a Swedish medical technology company specializing in the development of innovative neurostimulation treatments for chronic conditions. Established in 2005 and headquartered in Kista, Sweden, the company has developed and patented Ozilia®, a drug-free neuromodulation technology designed primarily to treat chronic migraine and chronic rhinitis. Ozilia® employs Kinetic Oscillation Stimulation, aiming to offer an alternative to medication by stimulating nerves to alleviate symptoms. The technology is CE-marked for use in the European Union and is marketed in selected European and Middle Eastern countries. By focusing on non-pharmaceutical approaches, Chordate Medical addresses large healthcare needs in respiratory and neurological domains, contributing to advancements in medical device-based therapies.